title: Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients.
abstract: BACKGROUND
  Epidemiologic data suggest that there is an association between vitamin D deficiency and influenza infection. We conducted a prospective influenza vaccination study to determine the influence of vitamin D status on serological response to influenza vaccine in prostate cancer (CaP) patients.
  
  
  METHODS
  During the 2006-2007 influenza season, CaP patients treated at Roswell Park Cancer Institute were offered vaccination with the trivalent influenza vaccine (Fluzone®, 2006-2007) and sera collected for hemagglutination inhibition (HI) assay titers before and 3 months after vaccination. Response to vaccination was defined as ≥1:40 titer ratio or a fourfold increase in titer at 3 months, against any of the three strains. Serum 25-hydroxyvitamin D (25-D₃) levels were measured using DiaSorin ¹²⁵I radioimmunoassay kits.
  
  
  RESULTS
  Thirty-five patients with CaP participated in the study. Median baseline 25-D₃ level was 44.88 ng/ml (range: 9.16-71.98 ng/ml) Serological response against any of the three strains was noted in 80%. There was a significant effect of baseline 25-D3 level when tested as a continuous variable in relation to serological response (P = 0.0446). All patients in the upper quartile of 25-D3 level responded by mounting a serological response (P = 0.0344). None of the other baseline variables (age, race, chemotherapy status, or white cell count) had an effect on serological response.
  
  
  CONCLUSIONS
  In this study in CaP patients, a replete vitamin D status was associated with more frequent serological response to influenza vaccine.
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.
authors.forename: Manpreet K
authors.initials: MK
authors.lastname: Chadha
authors.forename: Marwan
authors.initials: M
authors.lastname: Fakih
authors.forename: Josephia
authors.initials: J
authors.lastname: Muindi
authors.forename: Lili
authors.initials: L
authors.lastname: Tian
authors.forename: Terry
authors.initials: T
authors.lastname: Mashtare
authors.forename: Candace S
authors.initials: CS
authors.lastname: Johnson
authors.forename: Donald
authors.initials: D
authors.lastname: Trump
mesh_terms: D000368:Aged; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000097:blood / Q000276:immunology*; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000097:blood
chemical_list: D007252:Influenza Vaccines; D014807:Vitamin D; C104450:25-hydroxyvitamin D
references.citation: J Nutr. 2005 Feb;135(2):317-22
references.pmid: 15671234
references.citation: Br J Cancer. 1999 Apr;80(1-2):219-20
references.pmid: 10389999
references.citation: Cancer. 1979 Nov;44(5):1629-35
references.pmid: 498034
references.citation: N Engl J Med. 1973 Dec 13;289(24):1267-71
references.pmid: 4127183
references.citation: FASEB J. 2005 Jul;19(9):1067-77
references.pmid: 15985530
references.citation: Exp Lung Res. 2007 Dec;33(10):537-42
references.pmid: 18075828
references.citation: BJU Int. 2009 Oct;104(7):909-14
references.pmid: 19426195
references.citation: J Clin Oncol. 2002 Nov 1;20(21):4313-8
references.pmid: 12409329
references.citation: J Laryngol Otol. 2010 May;124(5):465-9
references.pmid: 20067648
references.citation: Virol J. 2008 Feb 25;5:29
references.pmid: 18298852
references.citation: Am J Clin Nutr. 2010 May;91(5):1255-60
references.pmid: 20219962
references.citation: Rev Infect Dis. 1985 Sep-Oct;7(5):613-8
references.pmid: 3903940
references.citation: Epidemiol Infect. 2007 Oct;135(7):1095-6; author reply 1097-8
references.pmid: 17352842
references.citation: Curr Top Microbiol Immunol. 2006;306:153-82
references.pmid: 16909921
references.citation: Int J Colorectal Dis. 2009 Feb;24(2):219-24
references.pmid: 18830610
references.citation: Nat Med. 2006 Apr;12(4):388-90
references.pmid: 16598282
references.citation: Drugs. 2000 Jul;60(1):35-53
references.pmid: 10929929
references.citation: J Immunol. 2004 Sep 1;173(5):2909-12
references.pmid: 15322146
references.citation: Epidemiol Infect. 2006 Dec;134(6):1129-40
references.pmid: 16959053
references.citation: Vaccine. 1999 Apr 9;17(15-16):1883-8
references.pmid: 10217585
references.citation: Epidemiol Infect. 1987 Aug;99(1):5-54
references.pmid: 3301379